Mehmet Altan

Mehmet Altan is a Professor of Medicine in the Department of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center. His research focuses on cancer immunotherapy, radiation oncology, and translational lung cancer research, with a particular emphasis on ALK-rearranged and EGFR-mutant non-small-cell lung cancer. He leads clinical trials integrating liquid biopsy and circulating tumor DNA methylation to predict outcomes, and his recent work includes the OncoTwin digital twin framework for treatment response prediction)Skip, the NorthStar phase II trial of osimertinib with local consolidative therapy, and machine-learning strategies for adapting immunotherapy in metastatic NSCLC. His publications appear in Nature Communications, the Journal of Thoracic Oncology, and Annals of Oncology.